Novo Nordisk A/S
F:NOVC

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
F:NOVC
Watchlist
Price: 90.7 EUR -1.52%
Market Cap: 203.5B EUR

Relative Value

The Relative Value of one NOVC stock under the Base Case scenario is hidden EUR. Compared to the current market price of 90.7 EUR, Novo Nordisk A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVC Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
18
Median 3Y
10.9
Median 5Y
9.9
Industry
2.6
Forward
5.1
vs History
90
vs Industry
21
Median 3Y
34.9
Median 5Y
29.4
Industry
21.4
Forward
15.2
vs History
92
vs Industry
23
Median 3Y
25.1
Median 5Y
23.1
Industry
16.4
vs History
85
vs Industry
24
Median 3Y
32.9
Median 5Y
24.5
Industry
22.8
vs History
92
vs Industry
3
Median 3Y
24.2
Median 5Y
20.2
Industry
2.2
vs History
92
vs Industry
16
Median 3Y
11
Median 5Y
9.9
Industry
2.9
Forward
5.3
vs History
90
vs Industry
22
Median 3Y
13.1
Median 5Y
11.9
Industry
5.5
vs History
90
vs Industry
25
Median 3Y
23.3
Median 5Y
21.4
Industry
13
Forward
10.9
vs History
90
vs Industry
25
Median 3Y
25.6
Median 5Y
23.4
Industry
16.5
Forward
12.6
vs History
90
vs Industry
23
Median 3Y
25
Median 5Y
23.1
Industry
15.6
vs History
68
vs Industry
15
Median 3Y
33.1
Median 5Y
29.7
Industry
18.7
vs History
92
vs Industry
13
Median 3Y
9.6
Median 5Y
8.7
Industry
1.9

Multiples Across Competitors

NOVC Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
F:NOVC
1.6T EUR 5.1 15.4 10.7 12.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
492.8B USD 5.3 19.6 16.1 20.8
CH
Roche Holding AG
SIX:ROG
264.6B CHF 4.3 28 12 14
UK
AstraZeneca PLC
LSE:AZN
220.5B GBP 5.1 31.7 108.8 159.2
CH
Novartis AG
SIX:NOVN
216.5B CHF 4.9 18.9 12 15.5
US
Merck & Co Inc
NYSE:MRK
270.8B USD 4.2 14.2 10.1 12
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.6B USD 2.3 14.7 7.5 10.2
FR
Sanofi SA
PAR:SAN
99.5B EUR 1.5 7.3 6.6 6.6
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
F:NOVC
Average P/E: 22.7
15.4
3%
5.1
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
37%
0.9
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
FR
Sanofi SA
PAR:SAN
7.3
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
F:NOVC
Average EV/EBITDA: 400.5
10.7
1%
10.7
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
6.6
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
F:NOVC
Average EV/EBIT: 1 712.9
12.5
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5
FR
Sanofi SA
PAR:SAN
6.6
15%
0.4